Fig. 1From: Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategyPancreatic cancer targeted therapies described in the review. ①nivolumab, pembrolizumab, toripalimab; ②durvalumab, avelumab, atezolizumab; ③PEGPH20; ④paricalcitol; ⑤galunisertib, M7824, LY2157299; ⑥cabiralizumab, lacnotuzumab; ⑦APX005M; ⑧BL-8040, AMD3100; ⑨NOX-A12; ⑩SX-682; ⑪defactinib; ⑫acalabrutinib; ⑬niraparib, BGB-290. BTK: Bruton’s tyrosine kinase; CAF: carcinoma-associated fibroblast; CSF1R: colony stimulating factor 1; CXCL12: CXC-chemokine ligand 12; CXCR2: CXC-chemokine receptor 2; CXCR4: CXC-chemokine receptor 4; FAK: focal adhesion kinase; FAP: fibroblast activation protein; HA: hyaluronic acid; HMGB1: high-mobility group protein B1; IL-6R: interleukin-6 receptor; MDSC: myeloid-derived suppressor cell; PARP: Poly (ADP-ribose) polymerase; PC: pancreatic cancer; PD-1: programmed cell death protein 1; PD-L1: programmed cell death ligand 1; PSC: pancreatic stellate cell; PSC*: activated pancreatic stellate cell; TAM: tumor-associated macrophage; TGFβR: transforming growth factor-β receptor; VDR: vitamin D receptorBack to article page